{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T10:00:43Z","timestamp":1792404043818,"version":"4.4.0"},"reference-count":46,"publisher":"Pharmaceutical Society of Japan","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,2,13]]},"DOI":"10.1248\/bpb.b25-00646","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T22:08:16Z","timestamp":1770934096000},"page":"301-309","source":"Crossref","is-referenced-by-count":2,"title":["Development and Clinical Application of a Simultaneous Liquid Chromatography\u2013Tandem Mass Spectrometry Method for Patients with Graft-versus-Host Disease to Quantify the Plasma Concentrations of Ruxolitinib and Posaconazole"],"prefix":"10.1248","volume":"49","author":[{"given":"Masaki","family":"Kumondai","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai 980\u20138574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagomi","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Tohoku University, Sendai 980\u20130845, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai 980\u20138574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai 980\u20138574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Otsuki","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai 980\u20138574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Ueki","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai 980\u20138574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Onishi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tohoku University Hospital, Sendai 980\u20138574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Tsukamoto","sequence":"additional","affiliation":[{"name":"Shimadzu Corporation, Kyoto 604\u20138511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Shimadzu Corporation, Kyoto 604\u20138511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"Shimadzu Corporation, Kyoto 604\u20138511, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai 980\u20138574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai 980\u20138574, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai 980\u20138574, Japan"},{"name":"Faculty of Pharmaceutical Sciences, Tohoku University, Sendai 980\u20130845, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai 980\u20138574, Japan"},{"name":"Faculty of Pharmaceutical Sciences, Tohoku University, Sendai 980\u20130845, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamitsu","family":"Maekawa","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai 980\u20138574, Japan"},{"name":"Faculty of Pharmaceutical Sciences, Tohoku University, Sendai 980\u20130845, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nariyasu","family":"Mano","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai 980\u20138574, Japan"},{"name":"Faculty of Pharmaceutical Sciences, Tohoku University, Sendai 980\u20130845, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Malard F, Holler E, Sandmaier BM, Huang H, Mohty M. Acute graft-versus-host disease. <i>Nat. Rev. Dis. Primers<\/i>, <b>9<\/b>, 27 (2023).","DOI":"10.1038\/s41572-023-00438-1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Amanam I, Otoukesh S, Al Malki MM, Salhotra A. Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies. <i>Hematology (Am. Soc. Hematol. Educ. Program)<\/i>, <b>2023<\/b>, 164\u2013170 (2023).","DOI":"10.1182\/hematology.2023000427"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Filipovich AH, Weisdorf D, Pavletic S, <i>et al<\/i>. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. <i>Biol. Blood Marrow Transplant.<\/i>, <b>11<\/b>, 945\u2013956 (2005).","DOI":"10.1016\/j.bbmt.2005.10.001"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Auletta JJ, Kou J, Chen M, <i>et al<\/i>. Real-world data showing trends and outcomes by race and ethnicity in allogeneic hematopoietic cell transplantation: a report from the Center for International Blood and Marrow Transplant Research. <i>Transplant. Cell. Ther.<\/i>, <b>29<\/b>, 346.e1\u2013346.e10 (2023).","DOI":"10.1016\/j.jtct.2023.03.007"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Ramdial JL, Mehta RS, Saliba RM, Alousi AM, Bashir Q, Hosing C, Kebriaei P, Olson AL, Oran B, Qazilbash MH, Srour SA, Andersson BS, Champlin RE, Popat U. Acute graft-versus-host disease is the foremost cause of late nonrelapse mortality. <i>Bone Marrow Transplant.<\/i>, <b>56<\/b>, 2005\u20132012 (2021).","DOI":"10.1038\/s41409-021-01274-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Axt L, Naumann A, Toennies J, Haen SP, Vogel W, Schneidawind D, Wirths S, Moehle R, Faul C, Kanz L, Axt S, Bethge WA. Retrospective single center analysis of outcome, risk factors and therapy in steroid refractory graft-versus-host disease after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplant.<\/i>, <b>54<\/b>, 1805\u20131814 (2019).","DOI":"10.1038\/s41409-019-0544-y"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Martini DJ, Chen YB, DeFilipp Z. Recent FDA approvals in the treatment of graft-versus-host disease. <i>Oncologist<\/i>, <b>27<\/b>, 685\u2013693 (2022).","DOI":"10.1093\/oncolo\/oyac076"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) De Togni E, Cole O, Abboud R. Janus kinase inhibition in the treatment and prevention of graft-versus-host disease. <i>Front. Immunol.<\/i>, <b>15<\/b>, 1304065 (2024).","DOI":"10.3389\/fimmu.2024.1304065"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Becker H, Engelhardt M, von Bubnoff N, W\u00e4sch R. Ruxolitinib. <i>Recent Results Cancer Res.<\/i>, <b>201<\/b>, 249\u2013257 (2014).","DOI":"10.1007\/978-3-642-54490-3_16"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Yang Y, Huo Y, Zhou D, Kang Z, Huang Y, Wang Y, Fan G, Ma L, Yan J. Efficacy and safety of Ruxolitinib combined with steroids for first-line treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation: a single-center, real-world experience. <i>Front. Immunol.<\/i>, <b>16<\/b>, 1621708 (2025).","DOI":"10.3389\/fimmu.2025.1621708"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Baccelli F, Gottardi F, Muratore E, Leardini D, Grasso AG, Gori D, Belotti T, Prete A, Masetti R. Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis. <i>Bone Marrow Transplant.<\/i>, <b>59<\/b>, 765\u2013776 (2024).","DOI":"10.1038\/s41409-024-02252-z"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) DeFilipp Z, Kim HT, Knight LW, O\u2019Connor SM, Dhaver SE, White M, Dholaria B, Schroeder MA, Vasu S, Abedin S, Chung J, El-Jawahri A, Frigault MJ, McAfee S, Newcomb RA, O\u2019Donnell PV, Spitzer TR, Chen YB, Hobbs GS. Low rates of chronic graft-versus-host disease with Ruxolitinib maintenance following allogeneic HCT. <i>Blood<\/i>, <b>145<\/b>, 2312\u20132316 (2025).","DOI":"10.1182\/blood.2024028005"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. <i>Pharmacol. Ther.<\/i>, <b>138<\/b>, 103\u2013141 (2013).","DOI":"10.1016\/j.pharmthera.2012.12.007"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Hendriks DFG, Vorrink SU, Smutny T, Sim SC, Nordling \u00c5., Ullah S, Kumondai M, Jones BC, Johansson I, Andersson TB, Lauschke VM, Ingelman-Sundberg M. Clinically relevant cytochrome P450 3A4 induction mechanisms and drug screening in three-dimensional spheroid cultures of primary human hepatocytes. <i>Clin. Pharmacol. Ther.<\/i>, <b>108<\/b>, 844\u2013855 (2020).","DOI":"10.1002\/cpt.1860"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Kumondai M, Kikuchi M, Mizuguchi A, Hayashi N, Ui M, Hirama T, Okada Y, Sato Y, Sato T, Maekawa M, Mano N. Therapeutic drug monitoring of blood sirolimus and tacrolimus concentrations for polypharmacy management in a lymphangioleiomyomatosis patient taking two cytochrome P450 3A inhibitors. <i>Tohoku J. Exp. Med.<\/i>, <b>260<\/b>, 29\u201334 (2023).","DOI":"10.1620\/tjem.2023.J016"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Otsuki A, Kumondai M, Kobayashi D, Kikuchi M, Ueki Y, Sato Y, Hayashi N, Yagi A, Onishi Y, Onodera K, Ichikawa S, Fukuhara N, Yokoyama H, Maekawa M, Mano N. Plasma venetoclax concentrations in patients with acute myeloid leukemia treated with CYP3A4 inhibitors. <i>Yakugaku Zasshi<\/i>, <b>144<\/b>, 775\u2013779 (2024).","DOI":"10.1248\/yakushi.24-00018"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. <i>N. Engl. J. Med.<\/i>, <b>356<\/b>, 335\u2013347 (2007).","DOI":"10.1056\/NEJMoa061098"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Hayashi Y, Kanda Y, Nakamae H, Kanamori H, Ohashi K, Hidaka M, Yano S, Hatanaka K, Kohno A, Moriuchi Y, Ago H, Yamashita T, Takata T, Yoshida M, Hino M, Yamaguchi T, Fukuda T. Voriconazole <i>vs<\/i>. itraconazole for antifungal prophylaxis in patients with GVHD: a randomized trial. <i>Biol. Blood Marrow Transplant.<\/i>, <b>20<\/b> (supple.), S91  (2014).","DOI":"10.1016\/j.bbmt.2013.12.117"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Krishna G, Ma L, Prasad P, Moton A, Martinho M, O\u2019Mara E. Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers. <i>Expert Opin. Drug Metab. Toxicol.<\/i>, <b>8<\/b>, 1\u201310 (2012).","DOI":"10.1517\/17425255.2012.639360"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Godamudunage MP, Grech AM, Scott EE. Comparison of antifungal azole interactions with adult cytochrome P450 3A4 <i>versus<\/i> neonatal cytochrome P450 3A7. <i>Drug Metab. Dispos.<\/i>, <b>46<\/b>, 1329\u20131337 (2018).","DOI":"10.1124\/dmd.118.082032"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Maertens JA, Girmenia C, Br\u00fcggemann RJ, Duarte RF, Kibbler CC, Ljungman P, Racil Z, Ribaud P, Slavin MA, Cornely OA, Peter Donnelly JP, Cordonnier C. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. <i>J. Antimicrob. Chemother.<\/i>, <b>73<\/b>, 3221\u20133230 (2018).","DOI":"10.1093\/jac\/dky286"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Kably B, Launay M, Derobertmasure A, Lefeuvre S, Dannaoui E, Billaud EM. Antifungal drugs TDM: trends and update. <i>Ther. Drug Monit.<\/i>, <b>44<\/b>, 166\u2013197 (2022).","DOI":"10.1097\/FTD.0000000000000952"},{"key":"23","unstructured":"23) Mohammadpour N, Elyasi S, Vahdati N, Mohammadpour AH, Shamsara J. A review on therapeutic drug monitoring of immunosuppressant drugs. <i>Iran. J. Basic Med. Sci.<\/i>, <b>14<\/b>, 485\u2013498 (2011)."},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Ashbee HR, Barnes RA, Johnson EM, Richardson MD, Gorton R, Hope WW. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology. <i>J. Antimicrob. Chemother.<\/i>, <b>69<\/b>, 1162\u20131176 (2014).","DOI":"10.1093\/jac\/dkt508"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) van der Kleij MBA, Guchelaar NAD, Mathijssen RHJ, Versluis J, Huitema ADR, Koolen SLW, Steeghs N. Therapeutic drug monitoring of kinase inhibitors in oncology. <i>Clin. Pharmacokinet.<\/i>, <b>62<\/b>, 1333\u20131364 (2023).","DOI":"10.1007\/s40262-023-01293-9"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Isberner N, Kraus S, Grigoleit GU, Aghai F, Kurlbaum M, Zimmermann S, Klinker H, Scherf-Clavel O. Ruxolitinib exposure in patients with acute and chronic graft <i>versus<\/i> host disease in routine clinical practice-a prospective single-center trial. <i>Cancer Chemother. Pharmacol.<\/i>, <b>88<\/b>, 973\u2013983 (2021).","DOI":"10.1007\/s00280-021-04351-w"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Hirasawa T, Kikuchi M, Takasaki S, Kumondai M, Sato Y, Sato T, Imoto E, Hayakawa Y, Maekawa M, Mano N. High throughput LC\/ESI-MS\/MS method for simultaneous analysis of 20 oral molecular-targeted anticancer drugs and the active metabolite of sunitinib in human plasma. <i>Heliyon<\/i>, <b>9<\/b>, e16926 (2023).","DOI":"10.1016\/j.heliyon.2023.e16926"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Rappold BA. Review of the use of liquid chromatography-tandem mass spectrometry in clinical laboratories: Part II\u2014Operations. <i>Ann. Lab. Med.<\/i>, <b>42<\/b>, 531\u2013557 (2022).","DOI":"10.3343\/alm.2022.42.5.531"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Sato Y, Kondo H, Sato Y, Abe A, Kikuchi M, Sato T, Kumondai M, Yoshikawa K, Hayakawa Y, Maekawa M, Mano N. Development of simultaneous drug concentration measurement method using an automated pretreatment liquid chromatography\/tandem mass spectrometry system for therapeutic drug monitoring. <i>Pharmaceutics<\/i>, <b>16<\/b>, 1138 (2024).","DOI":"10.3390\/pharmaceutics16091138"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Zhao Y, Chen P, Dou L, Li F, Li M, Xu L, Chen J, Jia M, Huang S, Wang N, Luan S, Yang J, Bai N, Liu D. Co-administration with voriconazole doubles the exposure of Ruxolitinib in patients with hematological malignancies. <i>Drug Des. Devel. Ther.<\/i>, <b>16<\/b>, 817\u2013825 (2022).","DOI":"10.2147\/DDDT.S354270"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Appeldoorn TYJ, Munnink THO, Morsink LM, Hooge MNL, Touw DJ. Pharmacokinetics and pharmacodynamics of Ruxolitinib: a review. <i>Clin. Pharmacokinet.<\/i>, <b>62<\/b>, 559\u2013571 (2023).","DOI":"10.1007\/s40262-023-01225-7"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Selby PR, Heffernan AJ, Yeung D, Warner MS, Peake SL, Hahn U, Westley I, Shakib S, Roberts JA. Population pharmacokinetics of posaconazole in allogeneic haematopoietic stem cell transplant patients. <i>J. Antimicrob. Chemother.<\/i>, <b>79<\/b>, 567\u2013577 (2024).","DOI":"10.1093\/jac\/dkae006"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Passing H, Bablok W. A new biometrical procedure for testing the equality of measurements from two different analytical methods: application of linear regression procedures for method comparison studies in clinical chemistry, Part I. <i>J. Clin. Chem. Clin. Biochem.<\/i>, <b>21<\/b>, 709\u2013720 (1983).","DOI":"10.1515\/cclm.1983.21.11.709"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. <i>Lancet<\/i>, <b>327<\/b>, 307\u2013310 (1986).","DOI":"10.1016\/S0140-6736(86)90837-8"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Amrani ME, Gerencser L, Huitema ADR, Hack CE, van Luin M, van der Elst KCM. A generic sample preparation method for the multiplex analysis of seven therapeutic monoclonal antibodies in human plasma or serum with liquid chromatography-tandem mass spectrometry. <i>J. Chromatogr. A<\/i>, <b>1655<\/b>, 462489 (2021).","DOI":"10.1016\/j.chroma.2021.462489"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Maekawa M, Yokota M, Sato T, Sato Y, Kumondai M, Sato Y, Suzuka M, Kobayashi D, Sakamoto K, Matsuura M, Kikuchi M, Komatsu H, Fujii K, Ozeki Y, Tomita H, Mano N. Development of a simultaneous LC-MS\/MS analytical method for plasma: 16 antipsychotics approved in Japan and 4 drug metabolites. <i>Anal. Sci.<\/i>, <b>40<\/b>, 1749\u20131763 (2024).","DOI":"10.1007\/s44211-024-00619-2"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Kumondai M, Ogawa R, Hayashi N, Ishida Y, Oshikiri H, Sato Y, Kikuchi M, Sato Y, Sato T, Maekawa M, Mano N. Relevance of plasma lenvatinib concentrations and endogenous urinary cytochrome P450 3A activity biomarkers in clinical practice. <i>Pharmacol. Res. Perspect.<\/i>, <b>12<\/b>, e1241 (2024).","DOI":"10.1002\/prp2.1241"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Shi JG, Fraczkiewicz G, Williams WV, Yeleswaram S. Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with Ruxolitinib. <i>Clin. Pharmacol. Ther.<\/i>, <b>97<\/b>, 177\u2013185 (2015).","DOI":"10.1002\/cpt.30"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Nijhawan M, Godugu M, Saxena T, Farheen T, Dwivedi K. Pharmaceutical co-crystals of posaconazole for improvement of physicochemical properties. <i>Braz. J. Pharm. Sci.<\/i>, <b>58<\/b>, e191024 (2022).","DOI":"10.1590\/s2175-97902022e191024"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Jagasia M, Perales MA, Schroeder MA, Ali H, Shah NN, Chen YB, Fazal S, Dawkins FW, Arbushites MC, Tian C, Connelly-Smith L, Howell MD, Khoury HJ. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. <i>Blood<\/i>, <b>135<\/b>, 1739\u20131749 (2020).","DOI":"10.1182\/blood.2020004823"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Ali H, Tsai NC, Synold T, Mokhtari S, Tsia W, Palmer J, Stiller T, Al Malki M, Aldoss I, Salhotra A, Rahmanuddin S, Pullarkat V, Cai JL, Stein A, Forman SJ, Marcucci G, Mei M, Snyder DS, Nakamura R. Peritransplantation Ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. <i>Blood Adv.<\/i>, <b>6<\/b>, 1444\u20131453 (2022).","DOI":"10.1182\/bloodadvances.2021005035"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Greer ND. Posaconazole (Noxafil): a new triazole antifungal agent. <i>Proc. Bayl. Univ. Med. Cent.<\/i>, <b>20<\/b>, 188\u2013196 (2007).","DOI":"10.1080\/08998280.2007.11928283"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. <i>Clin. Infect. Dis.<\/i>, <b>45<\/b>, 1610\u20131617 (2007).","DOI":"10.1086\/523576"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Kung HC, Johnson MD, Drew RH, Saha-Chaudhuri P, Perfect JR. Clinical effectiveness of posaconazole <i>versus<\/i> fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study. <i>Cancer Med.<\/i>, <b>3<\/b>, 667\u2013673 (2014).","DOI":"10.1002\/cam4.225"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Fraissinet F, Pereira T, Violin A, Feugray G, Bach-Ngohou K, Brunel V. A novel fully-automated method to measure steroids in serum by liquid chromatography-tandem mass spectrometry. <i>J. Mass Spectrom. Adv. Clin. Lab<\/i>, <b>27<\/b>, 24\u201332 (2023).","DOI":"10.1016\/j.jmsacl.2022.12.004"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Khromov T, Dihazi GH, Brockmeyer P, Fischer A, Streit F. 24\/7 therapeutic drug monitoring of beta-lactam antibiotics with CLAM-2000. <i>Antibiotics<\/i>, <b>12<\/b>, 1526 (2023).","DOI":"10.3390\/antibiotics12101526"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/2\/49_b25-00646\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:26:24Z","timestamp":1771039584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/2\/49_b25-00646\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00646","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"article-number":"b25-00646"}}